choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Treanda

Treanda Newsletter
  • October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) 05 Mar 2025 21:57 GMT

    Actemra (tocilizumab) Drug reaction with eosinophilia and systemic symptoms FDA is evaluating the … (bendamustine hydrochloride) Treanda (bendamustine hydrochloride) Nephrogenic diabetes insipidus FDA is evaluating the …

  • Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity 10 Feb 2025 19:46 GMT

    … Pharmaceutical Indus Teva Pharmaceutical Industries, based in Israel, is the leading generic drug … has a portfolio of innovative medicines and biosimilars in three … and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract …

  • CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL 31 Mar 2025 22:20 GMT

    … (Treanda) and rituximab (Rituxan) in the first-line treatment … Medicine at University Hospital LMU Munich, and investigator in the trial … co-director of Clinical Trials at the University of … tinyurl.com/bdeb2kze FDA approves acalabrutinib with bendamustine …

  • FDA Approves Acalabrutinib Combo in Previously Untreated MCL 17 Jan 2025 03:15 GMT

    … the FDA granted acalabrutinib priority review and set a Prescription Drug User … of the combination treatment of acalabrutinib with bendamustine (Treanda) and rituximab … participation in another therapeutic clinical trial, among other criteria. Acalabrutinib, …

  • Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol 31 Dec 2024 19:22 GMT

    … in combination with bendamustine (Treanda) and rituximab (Rituxan … , suitable preventive medications included Pneumocystis jirovecii … ’ notion, stating that halting treatment with acalabrutinib … trial. The FDA granted priority review to a supplemental new drug …

  • Treatment Options in MCL: What Are the Best Practices? 12 Sep 2024 13:41 GMT

    … Hopkins University School of Medicine, in a presentation … need better options after treatment with Bruton tyrosine kinase … typically been bendamustine (Bendeka, Treanda) and rituximab (Rituxan), … a long list of pharmaceutical companies, including AbbVie, …

  • 4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know 30 May 2024 16:24 GMT

    … has a portfolio of innovative medicines and biosimilars in three main … , and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract … generic and specialty drug distributor. Key Indicators: Teva Pharmaceutical Indus's …

  • Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know 22 May 2024 16:41 GMT

    … Pharmaceutical Indus Teva Pharmaceutical Industries, based in Israel, is the leading generic drug … has a portfolio of innovative medicines and biosimilars in three … and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract …

  • What the Options Market Tells Us About Teva Pharmaceutical Indus 13 May 2024 19:08 GMT

    … has a portfolio of innovative medicines and biosimilars in three main … , and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract … generic and specialty drug distributor. Where Is Teva Pharmaceutical Indus Standing Right …

  • Treanda dosage 04 Apr 2024 13:19 GMT

    … and Drug Administration (FDA) to treat: Treanda belongs to a drug class called alkylating drugs. Treanda … treatment Treanda is not a long-term treatment option for CLL or NHL. Doctors … effects you may have with Treanda Other medical conditions you have can …

Satisfied with the content?

Continue to create your account.